Platelet membrane-functionalized hollow mesoporous Prussian blue nanomedicine for comprehensive thrombolytic management by targeted enhanced fibrinolysis and ROS scavenging

作者全名："Zhang, Wenli; Sun, Maoyuan; Liu, Yun; Zhang, Yu; Xu, Lian; Luo, Ying; Du, Qianying; Xu, Jie; Liu, Jia; Zhou, Jun; Ran, Haitao; Wang, Zhigang; Wang, Junrui; Guo, Dajing"

作者地址："[Zhang, Wenli; Liu, Yun; Zhang, Yu; Xu, Lian; Luo, Ying; Du, Qianying; Xu, Jie; Liu, Jia; Zhou, Jun; Wang, Junrui; Guo, Dajing] Chongqing Med Univ, Affiliated Hosp 2, Dept Radiol, Chongqing 400010, Peoples R China; [Sun, Maoyuan] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing 400010, Peoples R China; [Ran, Haitao; Wang, Zhigang] Chongqing Med Univ, Affiliated Hosp 2, Dept Ultrasound, Chongqing 400010, Peoples R China; [Ran, Haitao; Wang, Zhigang] Chongqing Med Univ, Affiliated Hosp 2, Chongqing Key Lab Ultrasound Mol Imaging, Chongqing 400010, Peoples R China"

通信作者："Wang, JR; Guo, DJ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Radiol, Chongqing 400010, Peoples R China."

来源：CHEMICAL ENGINEERING JOURNAL

ESI学科分类：ENGINEERING

WOS号：WOS:001064896400001

JCR分区：Q1

影响因子：13.3

年份：2023

卷号：474

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：Comprehensive thrombolysis; Platelet membrane; Fibrinolysis; ROS; Hollow mesoporous Prussian blue

摘要："Thrombotic diseases cause significant risks of disability and death worldwide. However, conventional thrombolytic drugs have short half-lives, poor targeting capabilities, limited therapeutic effects, and narrow therapeutic windows. Moreover, most basic studies focus only on thrombolytic efficiency and ignore the inflammatory factors that promote thrombosis progression, such as reactive oxygen species (ROS)-mediated oxidative stress. Therefore, to achieve comprehensive and effective thrombolytic management, both targeted thrombolytic therapy and the elimination of inflammatory factors must be achieved. In this study, we developed a platelet membrane (PM)-functionalized hollow mesoporous Prussian blue nanomedicine (HMPB-rtPA@PM), which was innovatively coassembled from two FDA-approved drugs (Prussian blue (PB) and alteplase (rtPA)) and showed marked advantages in both thrombi targeting and photothermal/pharmacological synergistic fibrinolysis. Moreover, HMPB-rtPA@PM exhibited the potential to inhibit platelet aggregation and regulate the inflammatory microenvironment by scavenging ROS. As expected, this nanomedicine not only achieved more efficient thrombolysis in both thrombus models but also delayed thrombosis progression through therapeutic visualiza-tion in the black tail model. Such rational therapeutic principle provides a broad platform for the comprehensive management of thrombotic diseases."

基金机构："National Natural Science Foundation of China [82271970, 81901807, 82102063, 81701650, 81971608]"

基金资助正文："This work was financially supported by the National Natural Science Foundation of China (Grant Nos. 81971608, 82271970, 81901807, 82102063 and 81701650) ."